☆ 4.8 Article

Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide

CA-A CANCER JOURNAL FOR CLINICIANS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Oncology

Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of US oncologists

Kathryn F. Mileham et al.

Summary: The study found that most oncologists in the United States conducted biomarker testing in patients with non-small-cell lung cancer, but the turnaround time of test results impacted treatment decisions. Community providers and generalists were more likely to initiate non-targeted treatment while waiting for results compared to academic providers.

CANCER MEDICINE (2022)

Add to Collection

Article Surgery

Computed tomography-guided lung biopsy for molecular tests: a meta-analysis

Jian-Hua Zhang et al.

Summary: CT-guided lung biopsy can effectively provide sufficient lung cancer samples for molecular testing, with the EGFR gene being the most frequently mutated gene.

KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2022)

Add to Collection

Article Oncology

Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice

Charu Aggarwal et al.

Summary: Genotyping is crucial for patients with metastatic non-squamous NSCLC, and analyzing ctDNA from liquid biopsy samples offers the potential to extend the benefits of genotyping. Tumor genotyping guides treatment decisions for advanced-stage NSCLC patients, with ctDNA testing emerging as a key non-invasive option. Through the integration of ctDNA-based genotyping into routine clinical practice, effective genotyping may be utilized in nearly all patients with advanced-stage NSCLC.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial

Corinne Faivre-Finn et al.

Summary: In the Phase 3, placebo-controlled PACIFIC trial, consolidative durvalumab after chemoradiotherapy showed significant improvements in overall survival and progression-free survival for patients with unresectable, stage III NSCLC, with consistent benefits observed approximately 4 years after treatment. Durvalumab demonstrated durable benefits with a higher 4-year survival rate and progression-free survival rate compared to placebo.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Review Oncology

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Christian Rolfo et al.

Summary: Although precision medicine has had mixed impact on clinical management of patients with advanced-stage cancer overall, the advances have been dramatic for NSCLC, specifically lung adenocarcinoma, due to genomic complexity and increasing number of druggable oncogene drivers. Liquid biopsy serves as a practical alternative source for investigating tumor-derived somatic alterations, offering a minimally invasive approach for selecting targeted therapies. The most extensively studied methodology is plasma circulating tumor DNA, which has wide adoption as an alternative to tissue tumor genotyping, particularly in solid tumors like NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC

Mari Mino-Kenudson et al.

Summary: The survey reveals heterogeneity in PD-L1 immunohistochemistry testing across regions and laboratories, highlighting the need for additional quality assurance measures, formal training, and standardized reporting.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Critical Care Medicine

Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer

Adam H. Fox et al.

Summary: There are significant differences among pulmonologists in the evaluation of advanced NSCLC, varying knowledge of available biomarkers and the importance of targeted therapies. Interventional training appears to drive improved knowledge and practice for biomarker testing more than practice setting, indicating the need for improvements in tissue acquisition and interdisciplinary coordination for universal and comprehensive testing for eligible patients.

CHEST (2021)

Add to Collection

Article Critical Care Medicine

Safety and Costs of Fndobronchial Ultrasound-Guided Nodal Aspiration and Mediastinoscopy

Francys C. Verdial et al.

CHEST (2020)

Add to Collection

Review Oncology

PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

Sylvie Lantuejoul et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

T. Mok et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Oncology

Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma

Kartik Anand et al.

CLINICAL LUNG CANCER (2020)

Add to Collection

Article Oncology

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

Matthew P. Smeltzer et al.

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

L. Paz-Ares et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Clinical Neurology

Epidemiology of Brain Metastases

Patricia Sacks et al.

NEUROSURGERY CLINICS OF NORTH AMERICA (2020)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations

Andreanne Gagne et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Clinical Neurology

Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics

Lena Boenig et al.

FRONTIERS IN NEUROLOGY (2019)

Add to Collection

Article Oncology

Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer

Kenneth L. Kehl et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

J. -C. Soria et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Respiratory System

Sensitivity of Initial Thoracentesis for Malignant Pleural Effusion Stratified by Tumor Type in Patients with Strong Evidence of Metastatic Disease

Horiana B. Grosu et al.

RESPIRATION (2018)

Add to Collection

Article Economics

Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions

Kathryn A. Phillips et al.

VALUE IN HEALTH (2018)

Add to Collection

Article Oncology

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer A Meta-Analysis

Chee Khoon Lee et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

Add to Collection

Review Respiratory System

Endobronchial ultrasound-guided transbronchial needle aspiration: Safe as it sounds

Preyas J. Vaidya et al.

RESPIROLOGY (2017)

Add to Collection

Article Oncology

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer

David L. Rimm et al.

JAMA ONCOLOGY (2017)

Add to Collection

Article Critical Care Medicine

The Eighth Edition Lung Cancer Stage Classification

Frank C. Detterbeck et al.

CHEST (2017)

Add to Collection

Article Pathology

Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer

Willemijne A. M. E. Schrijver et al.

MODERN PATHOLOGY (2016)

Add to Collection

Article Respiratory System

Etiology of Pleural Effusions: Analysis of More than 3,000 Consecutive Thoracenteses

Jose M. Porcel et al.

ARCHIVOS DE BRONCONEUMOLOGIA (2014)

Add to Collection

Article Medicine, General & Internal

Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.

Tony S. Mok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

Article Multidisciplinary Sciences

EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib

W Pao et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)

Add to Collection

Article Multidisciplinary Sciences

EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy

JG Paez et al.

SCIENCE (2004)

Add to Collection

Article Medicine, General & Internal

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

TJ Lynch et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.